Hepatic Tumor Pipeline Grows as 75+ Pharma Companies Advance Novel Liver Cancer Therapies, Finds DelveInsight | Can-Fite BioPharma, MiNA Therapeutics, Yiviva, Janssen, Coherus Oncology

DelveInsight's "Hepatic Tumor - Pipeline Insight, 2026" report provides comprehensive insights about 75+ companies developing several pipeline drugs in the Hepatic Tumor pipeline landscape. It covers the Hepatic Tumor pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Hepatic Tumor treatment landscape. Learn more about the evolving Hepatic Tumor pipeline today @ https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Hepatic Tumor Pipeline Report

• On April 22, 2026, TherVacB Phase I clinical data supported continued development for chronic hepatitis B patients who are at high risk of developing hepatocellular carcinoma (HCC).
• On April 13, 2026, Coherus Oncology Inc. announced a Phase II study to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab.
• On April 08, 2026, Pfizer announced a Phase IB/II study of PF-08634404 alone or with ipilimumab for the treatment of locally advanced or metastatic hepatocellular carcinoma (HCC).
• On February 20, 2026, Crinetics Pharmaceuticals Inc. announced a Phase 3 study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome.
• On February 09, 2026, Stanford University conducted a Phase II Trial of Real Time MRI Guided Adaptive Stereotactic Ablative Radiotherapy for Liver Cancers.
• In June 2025, Europe ratified the nivolumab plus ipilimumab regimen for first-line hepatocellular carcinoma (HCC) treatment, two months after the FDA approval.
• In May 2025, Galmed Pharmaceuticals' Aramchol markedly boosted Bayer's Regorafenib efficacy, significantly reducing hepatic tumor growth in preclinical models; a Phase 1b trial is scheduled for Q4 2025.
• In May 2025, Henlius' HLX13, an anti-CTLA-4 fully human monoclonal antibody biosimilar of ipilimumab, entered a Phase 1/3 clinical trial for unresectable advanced hepatocellular carcinoma in combination with nivolumab.
• Hepatocellular carcinoma (HCC) is the most common malignant hepatic tumor, accounting for approximately 90% of primary liver cancers.
• DelveInsight's Hepatic Tumor Pipeline Insight report depicts a robust clinical development space with 75+ active players working to develop 75+ pipeline therapies.

Download for updates and the latest revolution in Hepatic Tumor care @ https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Hepatic Tumor Emerging Drugs Profile

• Namodenoson: Can-Fite BioPharma
Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist currently in Phase III clinical development for the treatment of oncology diseases including advanced liver cancer (hepatocellular carcinoma). It has demonstrated potent anti-cancer and anti-inflammatory activity in preclinical models, with safety already established in Phase I and Phase II clinical studies. Can-Fite BioPharma is conducting advanced clinical trials to establish its efficacy as a potential new oral therapeutic option in the liver cancer market.

• MTL-CEBPA: MiNA Therapeutics
MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. It is designed to reduce immune suppression of myeloid cells by restoring C/EBP-a protein to normal levels using an RNA Activation mechanism. Currently, MTL-CEBPA is being evaluated in Phase II studies for the treatment of Hepatic Tumor.

• ETN101: Synthetic Drug Candidate
ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It works as multiple tyrosine kinase inhibitors (mTKI), inhibiting protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and downstream signaling pathways such as PI3K/AKT and RAS-MAPK. The drug is currently in Phase I stage of clinical trials for the treatment of Hepatic Tumor.

For more information on the Hepatic Tumor Emerging Drugs Profile, download DelveInsight's comprehensive Hepatic Tumor Pipeline Insight report @ https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Hepatic Tumor Pipeline Report Provides

• Detailed insights about companies developing therapies for Hepatic Tumor, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Hepatic Tumor treatment.
• Hepatic Tumor companies that are involved in targeted therapeutics development with respective active and inactive projects.
• Hepatic Tumor drugs under development based on stage of development, route of administration, mechanism of action, and molecular type.
• Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the Hepatic Tumor market.

Learn more about Hepatic Tumor drug opportunities in our comprehensive Hepatic Tumor pipeline report @ https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Hepatic Tumor Companies and Competitive Landscape

There are 75+ key companies, including Can-Fite BioPharma, MiNA Therapeutics, Yiviva, Tvardi Therapeutics, Biosion, Novartis, Roche, Janssen Research & Development, and others, developing therapies for Hepatic Tumor. Can-Fite BioPharma has its Hepatic Tumor drug candidate in the most advanced Phase III stage.

DelveInsight's Hepatic Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Hepatic Tumor products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Hepatic Tumor treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Hepatic Tumor Pipeline Report

• Coverage: Global
• Hepatic Tumor Companies: Can-Fite BioPharma, MiNA Therapeutics, Yiviva, Tvardi Therapeutics, Biosion, Novartis, Roche, Janssen Research & Development, and others.
• Hepatic Tumor Therapies: Namodenoson, MTL-CEBPA, ETN101, YIV-906, BST02, and other pipeline candidates.
• Hepatic Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hepatic Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.